JNJ News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

JN

Mkt Cap

$650.65B

Volume

6.30M

Next Earnings

October 13th

Chart Financials Earnings News About Dividends Insider Filings

Wall Street's Bull Case for Bristol Myers Squibb Is Getting LouderBristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers despite strong Q2 performance with $12.9B revenue and 153% EPS growth. The company's growth portfolio of newer drugs now accounts for nearly 60% of revenue and grew 15% year-over-year, offsetting concerns about patent expirations on legacy drugs. With a 3.95% dividend yield, $5B buyback program, and potential acquisition interest from AstraZeneca, analysts see significant upside potential as the market has underpriced the stock relative to its pipeline execution.The Motley Fool · Sep 20, 2026

Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?AstraZeneca's stock has declined following several late-stage pipeline failures including Wainua in ATTR-CM, Ultomiris in HSCT-TMA, volrustomig in NSCLC, and Etcamah in breast cancer. However, the company maintains a broad pipeline with over 20 expected high-value readouts in the next 18 months, particularly in oncology. The stock trades at a reasonable valuation of 16.29x forward earnings, below industry average, though 2026-2027 earnings estimates have been revised downward.Zacks Investment Research · Sep 18, 2026

J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?Johnson & Johnson's stock has risen 18.3% in three months, driven by strong Innovative Medicine segment growth (6.2% organic), successful new drug launches (Icotyde, Imaavy, Inlexzo), and progress on talc litigation resolution. The company targets $100 billion in 2026 revenues and expects double-digit growth excluding Stelara impact. However, J&J faces headwinds from Stelara's patent expiration, MedTech slowdown, and upcoming generic competition for other drugs. Despite these challenges, analysts recommend staying invested given the company's diversified portfolio, strong pipeline, and confident guidance.Zacks Investment Research · Sep 18, 2026

Johnson & Johnson (JNJ) Increases Yet Falls Behind Market: What Investors Need to KnowJohnson & Johnson stock gained 1.1% to $270.22 but underperformed the S&P 500's 1.14% gain. The company is expected to report Q3 earnings on October 13, 2026, with projected EPS of $2.96 (up 5.71% YoY) and revenue of $25.36 billion (up 5.71% YoY). However, JNJ trades at a premium valuation with a Forward P/E of 23.05 versus the industry average of 15.67, and holds a Zacks Rank of #3 (Hold).Zacks Investment Research · Sep 17, 2026

Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive LandscapeThe global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.GlobeNewswire Inc. · Sep 17, 2026

The Stock Market Looks Shaky Right Now. History Says Dividend Growth Stocks Are Exactly What You Want to Own.Amid current market volatility driven by high Treasury yields, elevated oil prices, and inflation concerns, dividend growth stocks offer a historically proven strategy for delivering higher returns with lower volatility. The iShares Core Dividend Growth ETF (DGRO) provides an easy way to invest in companies with at least five years of consecutive dividend growth, having delivered double-digit returns over multiple time periods with reduced volatility compared to the broader market.The Motley Fool · Sep 16, 2026

My Top 5 Favorite Stocks for an Uncertain MarketThe article recommends five resilient stocks suitable for uncertain market conditions: Johnson & Johnson (pharmaceutical and medtech leader with 28 billion-dollar products), Vertex Pharmaceuticals (cystic fibrosis treatment market leader with pipeline expansion), Costco (essential goods retailer with high membership renewal rates), Coca-Cola (beverage company with strong brands and free cash flow), and American Express (payment card company with affluent customer base). These companies offer stability through essential products, strong market positions, and consistent dividend payments.The Motley Fool · Sep 16, 2026

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient DemandThe CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic platforms. The U.S. dominates with $1.90 billion in 2025 market value, while diffuse large B-cell lymphoma represents the largest patient population with approximately 78,000 cases across the markets.GlobeNewswire Inc. · Sep 16, 2026

Immunotherapy Drugs Market 2026: Precision Medicine, Next-Generation Biologics and Expanding Cancer Indications Fuel Growth OpportunitiesThe global immunotherapy drugs market is experiencing significant growth driven by advances in biotechnology, rising demand for targeted treatments, and expanding therapeutic applications across cancer, autoimmune, and inflammatory diseases. Key growth factors include increasing disease burden, robust drug pipelines, personalized medicine adoption, and combination therapy development. The Americas and Europe remain dominant markets, while Asia-Pacific is emerging as a high-growth region. Major pharmaceutical and biotech companies are increasing R&D investments and collaboration to accelerate innovation.GlobeNewswire Inc. · Sep 15, 2026

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?The iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed fund offering broad exposure to the Healthcare-Pharma sector with $1.63 billion in assets. The ETF has delivered strong year-to-date returns of 20.69% and 45.67% over the past year, though it carries higher risk with a beta of 0.49 and standard deviation of 16.8%. It holds approximately 60 pharmaceutical companies with top holdings including Johnson & Johnson (22.21%), Eli Lilly, and Bristol Myers Squibb, and carries a Zacks ETF Rank of 3 (Hold).Zacks Investment Research · Sep 15, 2026

JN

JNJJohnson & Johnson

JNJ

Pay with—

Available Balance0.00

Your PositionYou don't own any JNJ yet.

Related Tickers

Earnings

Dividends

Last · Aug 25Quarterly

Amount$1.34

Yield1.99%

Annual$5.36